Looking for Sentiment Analysis? Discover the most popular stocks on Reddit by using our Sentiment Tracker
Market Cap 101.05M P/E - EPS this Y 14.30% Ern Qtrly Grth -
Income -27.03M Forward P/E -4.52 EPS next Y -27.10% 50D Avg Chg -19.00%
Sales - PEG - EPS past 5Y - 200D Avg Chg 55.00%
Dividend N/A Price/Book 2.07 EPS next 5Y - 52W High Chg -48.00%
Recommedations 1.70 Quick Ratio 3.96 Shares Outstanding 49.04M 52W Low Chg 257.00%
Insider Own 3.89% ROA -25.63% Shares Float 34.40M Beta 1.04
Inst Own 39.97% ROE -57.02% Shares Shorted/Prior 1.27M/1.38M Price 2.17
Gross Margin - Profit Margin - Avg. Volume 1,123,456 Target Price 7.63
Oper. Margin - Earnings Date May 6 Volume 198,968 Change -3.12%
About Corvus Pharmaceuticals, Inc.

Corvus Pharmaceuticals, Inc., a clinical stage biopharmaceutical company, focuses on the development and commercialization of immuno-oncology therapies. Its lead product candidate is Mupadolimab (CPI-006), an anti-CD73 monoclonal antibody, which is in Phase I/Ib clinical trial for non-small cell lung cancer and head and neck cancers. The company also develops CPI-818, a covalent inhibitor of ITK, which is in Phase I/Ib clinical trial to treat patients with various malignant T-cell lymphomas, as well as designed to inhibit the proliferation of certain malignant T-cells; and Ciforadenant (CPI-444), an oral, small molecule antagonist of the A2A receptor that is in Phase II clinical trial for patients with advanced or refractory renal cell cancer. Its preclinical stage products include CPI-182, an antibody designed to block inflammation and myeloid suppression; and CPI-935, an adenosine A2B receptor antagonist to prevent fibrosis. Corvus Pharmaceuticals, Inc. has a strategic collaboration with Angel Pharmaceuticals. Corvus Pharmaceuticals, Inc. was incorporated in 2014 and is based in Burlingame, California.

Corvus Pharmaceuticals, Inc. News
03/22/24 Corvus (CRVS) Upgraded to Buy: What Does It Mean for the Stock?
03/21/24 Corvus Pharmaceuticals, Inc. (NASDAQ:CRVS) Q4 2023 Earnings Call Transcript
03/20/24 Q4 2023 Corvus Pharmaceuticals Inc Earnings Call
03/19/24 Corvus Pharmaceuticals Provides Business Update and Reports Fourth Quarter and Full Year 2023 Financial Results
03/13/24 Corvus Pharmaceuticals to Provide Business Update and Fourth Quarter and Full Year 2023 Financial Results on March 19, 2024
03/09/24 We Think Corvus Pharmaceuticals (NASDAQ:CRVS) Needs To Drive Business Growth Carefully
02/12/24 Corvus Pharmaceuticals Presents Soquelitinib Preclinical Data at the Keystone Symposia on Systemic Autoimmune and Autoinflammatory Diseases
02/08/24 Corvus Pharmaceuticals Announces Orphan Drug Designation Granted to Soquelitinib for the Treatment of T Cell Lymphoma
02/06/24 Corvus Pharmaceuticals Appoints Jeffrey Arcara as Chief Business Officer
01/23/24 Corvus Pharmaceuticals Announces the Passing of Board Member Edith P. Mitchell
01/05/24 Individual investors in Corvus Pharmaceuticals, Inc. (NASDAQ:CRVS) are its biggest bettors, and their bets paid off as stock gained 20% last week
12/11/23 What Makes Corvus (CRVS) a New Buy Stock
12/09/23 Corvus Pharmaceuticals Presents New Interim Soquelitinib Data from its Phase 1/1b T Cell Lymphoma Trial
12/07/23 Are Medical Stocks Lagging Corvus Pharmaceuticals (CRVS) This Year?
11/21/23 Is Corvus Pharmaceuticals (CRVS) Stock Outpacing Its Medical Peers This Year?
11/08/23 Corvus Pharmaceuticals, Inc. (NASDAQ:CRVS) Q3 2023 Earnings Call Transcript
11/08/23 Q3 2023 Corvus Pharmaceuticals Inc Earnings Call
11/07/23 Corvus Pharmaceuticals Provides Business Update and Reports Third Quarter 2023 Financial Results
11/02/23 Corvus Pharmaceuticals to Present New Interim Soquelitinib Data from its Phase 1/1b T Cell Lymphoma Trial at the 65th American Society of Hematology (ASH) Annual Meeting & Exposition
11/01/23 Corvus Pharmaceuticals Announces Publication of Preclinical Data Demonstrating Potential of ITK Inhibition with Soquelitinib as a Novel Approach to T Cell-Mediated Inflammatory and Immune Diseases
CRVS Chatroom

User Image Jellysquid1 Posted - 16 hours ago

$CRVS Mizuho Bullshit Analysts! Oppenheimer one of the best With A RECENT $7.50 Target!

User Image Thestocktraderhubzee Posted - 16 hours ago

$CRVS Mizuho Maintains Neutral on Corvus Pharma, Maintains $3.5 Price Target

User Image Jellysquid1 Posted - 20 hours ago

$CRVS List of institution Holders

User Image Jellysquid1 Posted - 1 day ago

$CRVS

User Image Jellysquid1 Posted - 2 days ago

$CRVS

User Image Wilbean Posted - 4 days ago

$CRVS $23 billion AD market with a huge unmet need . Miller and team will have access to rolling data out of the trial as its patient and doctor blinded, very important. The more I read about AD the more I understand Millers move into this trial. Some were disappointed that it was prioritized over the solid tumor trial, but I have no doubt a solid tumor trial will be a top priority when they have successfully addressed the cash runway . AD is a much quicker way to a partnership and a very large unmet need. So much potential, but with limited resources Miller needs to be Very strategic about where he directs them. As the entire sector dips, the fast money in crvs has moved on. IMO, not a bad thing. I also believe a partnership is imminent. Enjoy the weekend.

User Image Orphan_Drug_Guy Posted - 5 days ago

$CRVS been doing some DD for a while here. In after hours for a starter position. GLTA!

User Image tradingjunk321 Posted - 5 days ago

$CRVS so true below! TRIL, FUSN, VKTX etc…. Think about it, but when others are fearful! I plan on grabbing 10k more of my Smidge bids hit! Have a great weekend!

User Image NickeNyfiken1934 Posted - 5 days ago

@AZona $CLSD $CRVS $MREO

User Image Jellysquid1 Posted - 5 days ago

$CRVS Thanks for the Cheap Shares!

User Image MedicalDoctorInvestor Posted - 5 days ago

$CRVS going sub $1 soon. Just want to point out that I was right even though many people argued with me.

User Image Jellysquid1 Posted - 5 days ago

$CRVS Partnership Interest! Read Quote….

User Image Berrinho91 Posted - 5 days ago

$CRVS what’s everybody’s targets on this? I guess most people are LT. how do you even define a MC for a drug where it’s TAM is north of $150B annually 😂

User Image Berrinho91 Posted - 6 days ago

$CRVS continued to DD on this over the last week. Data so far very compelling. The potential for soquelitinib seems incredibly high. Struggling to understand why the MC is below 100M. I’m thinking it’s due to still being early in the drugs life, cash on hand and risk of dilution. If data continues to be good I guess the drug will be approved late 2026 or 2027. IMHO this is a potential multi multi bagger or BO. Feel free to add any comments, I’m really pleased I come across this and delighted to be on board for the ride 🙋‍♂️

User Image Jellysquid1 Posted - 6 days ago

$CRVS NO THREAT! IV verses Oral! 👇👇👇👇👇👇

User Image abc12332 Posted - 6 days ago

$CRVS Looks like we won’t have the only approved treatment for relapsed refractory CTCL/PTCL if 818 ultimately gets approval. T Cell lymphoma drug denileukin diftitox already approved in Japan for CTCL and PTCL. They resubmitted their BLA at the FDA’s request which the FDA accepted. A decision is expected by August but it very likely will be approved. Response rates are very similar to 818, approximately 40% with duration of response of 6 months. It requires an infusion and likely more difficult to tolerate because it’s IL2 based although they claim it was well tolerated in the trial. https://www.cancernetwork.com/view/fda-accepts-resubmitted-bla-for-denileukin-diftitox-in-r-r-ctcl

User Image XCBatman Posted - 6 days ago

$CRVS Did some investigation between the new 10K and the old 10Q on CRVS' changing plans for the solid tumor trial. The language went from "...for clinical investigation in a monotherapy Phase 1 clinical trial of soquelitinib in solid tumors, which we plan to initiate in the first half of 2024." to "for clinical investigation in a monotherapy trial of soquelitinib in solid tumors. We are planning a Phase 1b/2 clinical trial..." So, they added discrete information on the trial, stating that it's a Phase 1b/2 trial, but dropped it from their timeline. Coupled with the information from Conrad's data where Atopic Dermatitis supports Autoimmune (Global Sales >>$60B) vs. Solid Tumors ($13B). I wonder if this pivot directly supports a yet-to-be-announced partnership, supported by Arcara's statement on the conference call that "...our preferred partnering strategy is to find partners with development and commercialization expertise in immune disease...".

User Image tradingjunk321 Posted - 1 week ago

$CRVS I’m on deck!

User Image Wilbean Posted - 1 week ago

$CRVS The herd is always predictable. Relying on others for your information instead of doing your own DD will always result in a lack of conviction in the end. I will be buying more today if it continues to dip.

User Image Jellysquid1 Posted - 1 week ago

$CRVS Did some smidging! Could not resist at these prices!

User Image Jellysquid1 Posted - 1 week ago

$CRVS Oppenheimer Maintains an OUTPERFORM Rating After Yesterdays Earnings Report!

User Image XCBatman Posted - 1 week ago

$CRVS Glad to see that my math was close!

User Image Jellysquid1 Posted - 1 week ago

$CRVS Everybody should take 25 minutes and read for yourself what was said in yesterdays Earnings call found below on Yahoo. I am a believer in Richard Miller! Crvs will be a Winner! 👇👇👇👇👇👇👇

User Image Thestocktraderhubzee Posted - 1 week ago

$CRVS Oppenheimer Maintains Outperform on Corvus Pharma, Lowers Price Target to $7

User Image tradingjunk321 Posted - 1 week ago

$CRVS I listened to the CC, I read the CC transcript, my thoughts are everything is on track. I think some maybe digging to deep causing some confusion. My perspective is very clear, there are things coming in the short term, and from the sound of the CC more than one partnership. Below a couple of exciting points from Miller and Arcara:

User Image WalterBean Posted - 1 week ago

$CRVS updated its Presentation Deck today. See: https://corvuspharma.gcs-web.com/static-files/92bbf080-242a-4df2-be46-f6025a199adc

User Image kenyonn2016 Posted - 1 week ago

$CRVS where is this 14/25 or 56% response rate for ciforadenant coming from? There’s no data in the press release and I certainly didn't hear that in the call. I would love to believe it and it would be huge news if true. But I suspect the stock would have doubled after hours if that were the case.

User Image abc12332 Posted - 1 week ago

$CRVS Anyone who listened to the CC would appreciate your synopsis. No mention of the solid tumor Soquelitinib trial in the press release was a little concerning.

User Image Stonksiguess Posted - 1 week ago

$CRVS I’ll be shocked if this is not up big tomorrow. personally hoping the reaction stays muted so I can get more

User Image tradingjunk321 Posted - 1 week ago

$CRVS

Analyst Ratings
Mizuho Neutral Mar 27, 24
Oppenheimer Outperform Mar 20, 24
Cantor Fitzgerald Overweight Sep 7, 23
Mizuho Neutral Jun 16, 23
Ladenburg Thalmann Buy May 30, 23
Cantor Fitzgerald Overweight May 9, 23
Mizuho Neutral Mar 30, 23
Ladenburg Thalmann Buy Oct 7, 22
Cantor Fitzgerald Overweight Dec 3, 21
Insider Trades Relationship Date Transactions Cost($) #Shares Value($) #Share Own SEC Form 4
Jones William Benton See Remarks See Remarks Dec 20 Buy 0.79 20,000 15,800 133,773 12/20/22
MILLER RICHARD A MD President and CEO President and CEO Sep 28 Buy 0.7628 25,000 19,070 1,394,405 09/28/22
MILLER RICHARD A MD President and CEO President and CEO Sep 20 Buy 0.82 20,000 16,400 1,369,405 09/20/22
MILLER RICHARD A MD President and CEO President and CEO Jun 24 Buy 1.01 10,000 10,100 1,349,405 06/28/22
MILLER RICHARD A MD President and CEO President and CEO Jun 02 Buy 0.99 5,890 5,831 1,339,405 06/06/22
LEA LEIV Chief Financial Offi.. Chief Financial Officer Mar 16 Buy 1.6 49,038 78,461 99,238 03/17/22
MILLER RICHARD A MD President and CEO President and CEO Mar 15 Buy 1.53 30,000 45,900 1,318,515 03/17/22